NEW YORK, NY / ACCESSWIRE / October 9, 2017 / U.S. markets pulled back Friday as data showed U.S. nonfarm jobs declined for the first time in seven years. The Dow Jones Industrial Average declined 0.01 percent to close at 22,773.67, while the S&P 500 Index fell 0.11 percent to close at 2,549.33. The NASDAQ Composite Index gained 0.07 percent to close at 6,590.18. On Friday, the Bureau of Labor Statistics reported payrolls fell by 33,000 in September. Economists' expectations called for an increase of 90,000 in September, according to economists surveyed by Reuters.
"Markets had been ludicrously overbought, with the S&P 500 rising for eight straight days by Thursday. Markets could have dropped even if we did not have a negative reading on the jobs report," said Michael Antonelli, equity sales trader at Robert W. Baird & Co., according to MarketWatch.
"The reaction on the market suggests that nothing has changed when it comes to rate hikes in December," Antonelli said.
RDI Initiates Coverage on:
Cytori Therapeutics Inc
Repros Therapeutics Inc.
Cytori Therapeutics Inc.'s stock jumped 29.55% Friday, to close the day at $0.63. The stock recorded a trading volume of 19,354,894 shares, which was above its three months average volume of 1,114,780 shares. In the last year, Cytori Therapeutics Inc.'s shares have traded in a range of 0.28 - 2.13. The share price has gained 124.31% from its 52-week low. The company's shares are currently trading below their 200-day moving average. Moreover, the stock's 50-day moving average of $0.37 is below its 200-day moving average of $0.84. Shares of Cytori Therapeutics have fallen approximately 57.96 percent year-to-date.
Access RDI's Cytori Therapeutics Inc. Research Report at:
On Friday, shares in Repros Therapeutics Inc. recorded a trading volume of 12,361,133 shares, which was above the three months average volume of 794,778 shares. The stock ended the day 64.80% higher at 0.53. The share price has gained 103.85% from its 52-week low with a 52-week trading range of 0.26 - 2.18.The company's shares are currently trading below their 200-day moving average. Moreover, the stock's 50-day moving average of $0.32 is below its 200-day moving average of $0.57. Shares of Repros Therapeutics have gained approximately 63.13 percent year-to-date.
Access RDI's Repros Therapeutics Inc. Research Report at:
Research Driven Investing
We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.
RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.
Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker-dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.
For any questions, inquiries, or comments reach out to us directly at:
Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.